Robin Zon
Expertise in
6
conditions

Dr. Robin Zon

Oncology
Michiana Hematology-Oncology P C
5340 Holy Cross Pkwy, 
Mishawaka, IN 
Expertise in
6
conditions
Michiana Hematology-Oncology P C
5340 Holy Cross Pkwy, 
Mishawaka, IN 

Overview

Robin Zon is an Oncologist practicing medicine in Mishawaka, Indiana.

Dr. Zon is highly rated in 6 conditions, according to our data. Her clinical expertise encompasses Breast Cancer, Paget Disease of the Breast, Severe Congenital Neutropenia, and Lung Cancer.

She is actively involved in clinical research, co-authoring 38 peer reviewed articles and participating in 11 clinical trials.

Specialties

Oncology

Licenses

Internal Medicine in IN

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO

Locations

Michiana Hematology-Oncology P C
5340 Holy Cross Pkwy, Mishawaka, IN 46545
Other Locations
Office
100 E Wayne St Ste 510, South Bend, IN 46601

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Exemestane, Letrozole, Systemic Chemotherapy
Study Phase: Phase 3
A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients With Stage 0-III Colon or Rectal Cancer, Phase III - Preventing Adenomas of the Colon With Eflornithine and Sulindac (PACES)
A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients With Stage 0-III Colon or Rectal Cancer, Phase III - Preventing Adenomas of the Colon With Eflornithine and Sulindac (PACES)
Enrollment Status: Active_not_recruiting
Publish Date: April 02, 2026
Intervention Type: Drug
Study Phase: Phase 3
A Phase II-R and a Phase III Trial Evaluating Both Erlotinib (Ph II-R) and Chemoradiation (Ph III) as Adjuvant Treatment for Patients With Resected Head of Pancreas Adenocarcinoma
A Phase II-R and a Phase III Trial Evaluating Both Erlotinib (Ph II-R) and Chemoradiation (Ph III) as Adjuvant Treatment for Patients With Resected Head of Pancreas Adenocarcinoma
Enrollment Status: Completed
Publish Date: February 23, 2026
Intervention Type: Other, Procedure, Drug, Radiation
Study Drugs: Capecitabine, Chemotherapy, Erlotinib hydrochloride, Fluorouracil, Gemcitabine hydrochloride
Study Phase: Phase 3
Alternate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer Neoadjuvant Treatment (ALTERNATE) in Postmenopausal Women: A Phase III Study
Alternate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer Neoadjuvant Treatment (ALTERNATE) in Postmenopausal Women: A Phase III Study
Enrollment Status: Active_not_recruiting
Publish Date: January 22, 2026
Intervention Type: Drug
Study Drugs: Fulvestrant, Anastrozole
Study Phase: Phase 3
Effect of Preoperative Breast MRI on Surgical Outcomes, Costs and Quality of Life of Women With Breast Cancer
Effect of Preoperative Breast MRI on Surgical Outcomes, Costs and Quality of Life of Women With Breast Cancer
Enrollment Status: Completed
Publish Date: September 05, 2025
Intervention Type: Procedure
Study Phase: Phase 3
A Phase III Randomized, Double-Blind Placebo Controlled Study of Armodafinil (Nuvigil®) To Reduce Cancer-Related Fatigue in Patients With High Grade Glioma
A Phase III Randomized, Double-Blind Placebo Controlled Study of Armodafinil (Nuvigil®) To Reduce Cancer-Related Fatigue in Patients With High Grade Glioma
Enrollment Status: Completed
Publish Date: January 27, 2025
Intervention Type: Other, Drug
Study Phase: Phase 3
A Phase II Randomized Trial Comparing the Efficacy of Heat Shock Protein-Peptide Complex-96 (HSPPC-96) (NSC #725085, ALLIANCE IND # 15380) Vaccine Given With Bevacizumab Versus Bevacizumab Alone in the Treatment of Surgically Resectable Recurrent Glioblastoma Multiforme (GBM)
A Phase II Randomized Trial Comparing the Efficacy of Heat Shock Protein-Peptide Complex-96 (HSPPC-96) (NSC #725085, ALLIANCE IND # 15380) Vaccine Given With Bevacizumab Versus Bevacizumab Alone in the Treatment of Surgically Resectable Recurrent Glioblastoma Multiforme (GBM)
Enrollment Status: Terminated
Publish Date: January 24, 2025
Intervention Type: Biological, Drug
Study Drugs: HSPPC-96, Bevacizumab
Study Phase: Phase 2
A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: January 13, 2025
Intervention Type: Radiation, Procedure
Study Phase: Phase 3
A Phase II/III Trial of Neoadjuvant FOLFOX With Selective Use of Combined Modality Chemoradiation Versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection With Total Mesorectal Excision (PROSPECT)
A Phase II/III Trial of Neoadjuvant FOLFOX With Selective Use of Combined Modality Chemoradiation Versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection With Total Mesorectal Excision (PROSPECT)
Enrollment Status: Unknown
Publish Date: February 02, 2024
Intervention Type: Procedure, Other, Drug
Study Phase: Phase 2/Phase 3
A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)
A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)
Enrollment Status: Completed
Publish Date: June 01, 2023
Intervention Type: Biological, Drug, Other
View 9 Less Clinical Trials

37 Total Publications

A New Approach to Cancer Second Opinions: Overcoming the Challenges of Conventional Oncology Practice by Providing Education to Patients and Physicians.
A New Approach to Cancer Second Opinions: Overcoming the Challenges of Conventional Oncology Practice by Providing Education to Patients and Physicians.
Journal: Journal of cancer education : the official journal of the American Association for Cancer Education
Published: March 08, 2025
Similar Doctors
Expertise in
59
conditions
Dr. Bilal Ansari
Oncology
Expertise in
59
conditions
Dr. Bilal Ansari
Oncology

Michiana Hematology-Oncology P C

5340 Holy Cross Pkwy, 
Mishawaka, IN 
 (0.1 miles away)
574-237-1328
Languages Spoken:
English
See accepted insurances

Bilal Ansari is an Oncologist practicing medicine in Mishawaka, Indiana. Dr. Ansari is highly rated in 59 conditions, according to our data. His clinical expertise encompasses Pleuropulmonary Blastoma, Lung Cancer, Familial Colorectal Cancer, and Childhood Iron Deficiency Anemia.

Expertise in
53
conditions
Dr. Ebenezer Kio
Oncology
Expertise in
53
conditions
Dr. Ebenezer Kio
Oncology

Goshen Health

200 High Park Ave, 
Goshen, IN 
 (20.2 miles away)
574-364-2888
Languages Spoken:
English
See accepted insurances

Ebenezer Kio is an Oncologist practicing medicine in Goshen, Indiana. Dr. Kio is highly rated in 53 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Pleuropulmonary Blastoma, Non-Hodgkin Lymphoma, and Chronic Lymphocytic Leukemia (CLL).

Expertise in
32
conditions
Dr. Rolan Pascual
Oncology
Expertise in
32
conditions
Dr. Rolan Pascual
Oncology

Michiana Hematology-Oncology P C

5340 Holy Cross Pkwy, 
Mishawaka, IN 
 (0.1 miles away)
574-237-1328
Languages Spoken:
English
See accepted insurances

Rolan Pascual is an Oncologist practicing medicine in Mishawaka, Indiana. Dr. Pascual is highly rated in 32 conditions, according to our data. His clinical expertise encompasses Childhood Iron Deficiency Anemia, Pleuropulmonary Blastoma, Lung Cancer, and Colorectal Cancer.

Frequently Asked Questions about Dr. Robin Zon

How do I make an appointment with Dr. Robin Zon?

You can book an appointment with Dr. Robin Zon by calling their office at 574-237-1328. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Robin Zon a top-rated expert for Breast Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Robin Zon is classified as an Distinguished expert for Breast Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Robin Zon specialize in?

While Dr. Robin Zon is a Oncology, they have specific expertise in Breast Cancer, Paget Disease of the Breast, and Severe Congenital Neutropenia. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Robin Zon participate in research or clinical trials?

Yes. Dr. Robin Zon has published 37 articles and abstracts on conditions like Breast Cancer. You can view a list of Dr. Robin Zon's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Robin Zon accept my insurance?

Dr. Robin Zon accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 574-237-1328 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Zon's expertise for a condition
ConditionClose
    View All 49 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile